Elevated interleukin-10: A new cause of dyslipidemia leading to severe HDL deficiency

Journal of Clinical Lipidology

Volumn 9, Issue 1, 2015, Pages 81-90

  Moraitis, Andreas G ^a   Freeman, Lita A ^b   Shamburek, Robert D ^b   Wesley, Robert ^c   Wilson, Wyndham ^d   Grant, Cliona M ^d   Price, Susan ^c   Demosky, Stephen ^b   Thacker, Seth G ^b   Zarzour, Abdalrahman ^b   Hornung, Ronald L ^e   Pucino, Frank ^f   Csako, Gyorgy ^c   Yarboro, Cheryl ^f   McInnes, Iain B ^f,g   Kuroiwa, Takashi ^f   Boumpas, Dimitrios ^f,h   Rao, V Koneti ^c   Illei, Gabor G ^f   Remaley, Alan T ^b,c  

^a UNIVERSITY OF MICHIGAN   (United States)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^f NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

^g UNIVERSITY OF GLASGOW   (United Kingdom)

^h UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

"Disappearing HDL syndrome"; ALPS; B cell lymphoma; Dyslipidemia; Hypertriglyceridemia; IL 10; Intravascular large B cell; LCAT; Lymphoma; Psoriasis; Severe HDL deficiency

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 10; LACTATE DEHYDROGENASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; RITUXIMAB; TRIACYLGLYCEROL; VINCRISTINE; FAS ANTIGEN; FAS PROTEIN, HUMAN; RECOMBINANT PROTEIN;

ADULT; ANEMIA; ARTICLE; AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CASE REPORT; CHILD; COMPUTER ASSISTED TOMOGRAPHY; CYTOPENIA; DECREASED APPETITE; DISEASE SEVERITY; DYSLIPIDEMIA; ENZYME LINKED IMMUNOSORBENT ASSAY; FAILURE TO THRIVE; FEMALE; FEVER; HEMATOCRIT; HUMAN; HYPOALPHALIPOPROTEINEMIA; IMMUNOSUPPRESSIVE TREATMENT; LACTATE DEHYDROGENASE BLOOD LEVEL; LARGE CELL LYMPHOMA; LIMIT OF DETECTION; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; LONG TERM CARE; LYMPHADENOPATHY; MALE; MAXILLA SINUS TUMOR; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SINUS PAIN; SPLENOMEGALY; THROMBOCYTOPENIA; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION; WESTERN BLOTTING; ARTHRITIS, PSORIATIC; BIOSYNTHESIS; BLOOD; COHORT ANALYSIS; CONTROLLED STUDY; DYSLIPIDEMIAS; GENETICS; INFANT; LYMPHOMA, B-CELL; LYMPHOMA, LARGE B-CELL, DIFFUSE; PLACEBO EFFECT; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; ANTIGENS, CD95; ARTHRITIS, PSORIATIC; AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME; CHILD; CHOLESTEROL, HDL; CHOLESTEROL, LDL; COHORT STUDIES; DYSLIPIDEMIAS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INFANT; INTERLEUKIN-10; LYMPHOMA, B-CELL; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PLACEBO EFFECT; RECOMBINANT PROTEINS; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 84927587883     PISSN: 19332874     EISSN: 18764789     Source Type: Journal    
DOI: 10.1016/j.jacl.2014.09.014     Document Type: Article

References (52)

1. Toth PP, Barter PJ, Rosenson RS, et al. High-density lipoproteins: A consensus statement from the National Lipid Association. J Clin Lipidol. 2013;7:484-525.
2. Rader DJ, deGoma EM. Approach to the patient with extremely low HDL-cholesterol. J Clin Endocrinol Metab. 2012;97:3399-3407.
3. Goldberg RB, Mendez AJ. Severe acquired (secondary) high-density lipoprotein deficiency. J Clin Lipidol. 2007;1:41-56.
4. Park YB, Lee SK, Lee WK, et al. Lipid profiles in untreated patients with rheumatoid arthritis. J Rheumatol. 1999;26:1701-1704.
5. Myasoedova E, Crowson CS, Kremers HM, et al. Lipid paradox in rheumatoid arthritis: The impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann Rheum Dis. 2011;70:482-487.
6. de Carvalho JF, Bonfa E, Borba EF. Systemic lupus erythematosus and "lupus dyslipoproteinemia". Autoimmun Rev. 2008;7:246-250.
7. Khovidhunkit W, Kim MS, Memon RA, et al. Effects of infection and inflammation on lipid and lipoprotein metabolism: Mechanisms and consequences to the host. J Lipid Res. 2004;45:1169-1196.
8. Simonelli S, Gianazza E, Mombelli G, et al. Severe high-density lipoprotein deficiency associated with autoantibodies against lecithin:cholesterol acyltransferase in non-hodgkin lymphoma. Arch Intern Med. 2012;172:179-181.
9. McInnes IB, Illei GG, Danning CL, et al. Il-10 improves skin disease and modulates endothelial activation and leukocyte effector function in patients with psoriatic arthritis. Journal of Immunology. 2001;167:4075-4082.
10. Vaisman BL, Remaley AT. Measurement of lecithin-cholesterol acyltransferase activity with the use of a peptide-proteoliposome substrate. In: Freeman LA, editor. Lipoproteins and cardiovascular disease: Methods and protocols. Methods Mol Biol. New York: Springer, 2013. p. 343-352.
11. Oliveira JB, Bleesing JJ, Dianzani U, et al. Revised diagnostic criteria and classification for the autoimmune lymphoproliferative syndrome (ALPS): Report from the 2009 NIH international workshop. Blood. 2010;116:e35-e40.
12. Price S, Shaw PA, Seitz A, et al. Natural history of autoimmune lymphoproliferative syndrome associated with FAS gene mutations. Blood. 2014;123:1989-1999.
13. Fisher GH, Rosenberg FJ, Straus SE, et al. Dominant interfering FAS gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell. 1995;81:935-946.
14. Sneller MC, Straus SE, Jaffe ES, et al. A novel lymphoproliferative/ autoimmune syndrome resembling murine lpr/gld disease. J Clin Invest. 1992;90:334-341.
15. Ohashi N, Aomatsu M, Mori A, et al. Intravascular lymphoma with extremely low high-density lipoproteinemia. Intern Med. 2007;46:1475-1477.
16. Garg A, Hosfield EM, Brickner L. Disseminated intravascular large B cell lymphoma with slowly decreasing high-density lipoprotein cholesterol. South Med J. 2011;104:53-56.
17. Blackman JD, Cabana VG, Mazzone T. The acute-phase response and associated lipoprotein abnormalities accompanying lymphoma. J Intern Med. 1993;233:201-204.
18. Magerus-Chatinet A, Stolzenberg MC, Loffredo MS, et al. Fas-l, IL-10, and double-negative CD4- CD8- TCR alpha/beta+ T cells are reliable markers of autoimmune lymphoproliferative syndrome (ALPS) associated with fas loss of function. Blood. 2009;113:3027-3030.
19. Caminha I, Fleisher TA, Hornung RL, et al. Using biomarkers to predict the presence of FAS mutations in patients with features of the autoimmune lymphoproliferative syndrome. J Allergy Clin Immunol. 2010;125:946-949.e6.
20. Santos RD, Asztalos BF, Martinez LR, Miname MH, Polisecki E, Schaefer EJ. Clinical presentation, laboratory values, and coronary heart disease risk in marked high-density lipoprotein-deficiency states. J Clin Lipidol. 2008;2:237-247.
21. Asztalos BF, Tani M, Schaefer EJ. Metabolic and functional relevance of HDL subspecies. Curr Opin Lipidol. 2011;22:176-185.
22. Kalampokis I, Yoshizaki A, Tedder TF. Il-10-producing regulatory B cells (B10 cells) in autoimmune disease. Arthritis Res Ther. 2013;15(Suppl 1):S1.
23. Yao Y, Simard AR, Shi FD, Hao J. IL-10-producing lymphocytes in inflammatory disease. Int Rev Immunol. 2013;32:324-336.
24. Asadullah K, Sterry W, Volk HD. Interleukin-10 therapy-review of a new approach. Pharmacol Rev. 2003;55:241-269.
25. Wilke CM, Wei S, Wang L, Kryczek I, Kao J, Zou W. Dual biological effects of the cytokines interleukin-10 and interferon-gamma. Cancer Immunol Immunother. 2011;60:1529-1541.
26. Iyer SS, Cheng G. Role of interleukin 10 transcriptional regulation in inflammation and autoimmune disease. Crit Rev Immunol. 2012;32:23-63.
27. Muhl H. Pro-inflammatory signaling by IL-10 and IL-22: Bad habit stirred up by interferons? Front Immunol. 2013;4:18.
28. Soares NM, Leal TF, Fiuza MC, et al. Plasma lipoproteins in visceral leishmaniasis and their effect on leishmania-infected macrophages. Parasite Immunol. 2010;32:259-266.
29. Nylen S, Sacks D. Interleukin-10 and the pathogenesis of human visceral leishmaniasis. Trends Immunol. 2007;28:378-384.
30. Robertson J, Peters MJ, McInnes IB, Sattar N. Changes in lipid levels with inflammation and therapy in RA: A maturing paradigm. Nat Rev Rheumatol. 2013;9:513-523.
31. Gordon BR, Parker TS, Levine DM, et al. Relationship of hypolipidemia to cytokine concentrations and outcomes in critically ill surgical patients. Crit Care Med. 2001;29:1563-1568.
32. Spriggs DR, Sherman ML, Michie H, et al. Recombinant human tumor necrosis factor administered as a 24-hour intravenous infusion. A phase I and pharmacologic study. J Natl Cancer Inst. 1988;80:1039-1044.
33. Ahsan Lusana, Ossoli Alice F, Freeman Lita, Amar Marcelo J, Shamburek Robert D, Remaley Alan T. Role of lecithin: Cholesterol acyltransferase in HDL metabolism and atherosclerosis. In: Komoda T, editor. The HDL Handbook (Second Edition) Biological Functions and Clinical Implications. Academic Press, 2014. p. 159-194.
34. Cheung MC, Wang DB, Lum KD, Albers JJ. Cholesterol esterification by lecithin-cholesterol acyltransferase in A-I-free plasma. Biochim Biophys Acta. 1988;962:258-264.
35. Yao JK, Herbert PN, Fredrickson DS, et al. Biochemical studies in a patient with a Tangier syndrome. J Neuropathol Exp Neurol. 1978;37:138-154.
36. Santos RD, Schaefer EJ, Asztalos BF, et al. Characterization of high density lipoprotein particles in familial apolipoprotein A-I deficiency. J Lipid Res. 2008;49:349-357.
37. Yoshioka T, Okada T, Maeda Y, et al. Adeno-associated virus vector-mediated interleukin-10 gene transfer inhibits atherosclerosis in apolipoprotein E-deficient mice. Gene Ther. 2004;11:1772-1779.
38. Wolk K, Witte E, Reineke U, et al. Is there an interaction between interleukin-10 and interleukin-22? Genes Immun. 2005;6:8-18.
39. Bourreille A, Segain JP, Raingeard de la Bletiere D, et al. Lack of interleukin 10 regulation of antigen presentation-associated molecules expressed on colonic epithelial cells. Eur J Clin Invest. 1999;29:48-55.
40. Denning TL, Campbell NA, Song F, et al. Expression of IL-10 receptors on epithelial cells from the murine small and large intestine. Int Immunol. 2000;12:133-139.
41. Latorre E, Mendoza C, Matheus N, et al. Il-10 modulates serotonin transporter activity and molecular expression in intestinal epithelial cells. Cytokine. 2013;61:778-784.
42. Green PH, Lefkowitch JH, Glickman RM, Riley JW, Quinet E, Blum CB. Apolipoprotein localization and quantitation in the human intestine. Gastroenterology. 1982;83:1223-1230.
43. Magun AM, Brasitus TA, Glickman RM. Isolation of high density lipoproteins from rat intestinal epithelial cells. J Clin Invest. 1985;75:209-218.
44. Naganawa S, Ginsberg HN, Glickman RM, Ginsburg GS. Intestinal transcription and synthesis of apolipoprotein A-I is regulated by five natural polymorphisms upstream of the apolipoprotein CIII gene. J Clin Invest. 1997;99:1958-1965.
45. Mallat Z, Heymes C, Ohan J, Faggin E, Leseche G, Tedgui A. Expression of interleukin-10 in advanced human atherosclerotic plaques: Relation to inducible nitric oxide synthase expression and cell death. Arterioscler Thromb Vasc Biol. 1999;19:611-616.
46. Mallat Z, Besnard S, Duriez M, et al. Protective role of interleukin-10 in atherosclerosis. Circ Res. 1999;85:e17-24.
47. Pinderski Oslund LJ, Hedrick CC, Olvera T, et al. Interleukin-10 blocks atherosclerotic events in vitro and in vivo. Arterioscler Thromb Vasc Biol. 1999;19:2847-2853.
48. Pinderski LJ, Fischbein MP, Subbanagounder G, et al. Overexpression of interleukin-10 by activated T lymphocytes inhibits atherosclerosis in LDL receptor-deficient mice by altering lymphocyte and macrophage phenotypes. Circ Res. 2002;90:1064-1071.
49. Han X, Kitamoto S, Wang H, Boisvert WA. Interleukin-10 overexpression in macrophages suppresses atherosclerosis in hyperlipidemic mice. FASEB J. 2010;24:2869-2880.
50. Tziakas DN, Chalikias GK, Hatzinikolaou HI, et al. Anti-inflammatory cytokine profile in acute coronary syndromes: Behavior of interleukin-10 in association with serum metalloproteinases and proinflammatory cytokines. Int J Cardiol. 2003;92:169-175.
51. Malarstig A, Eriksson P, Hamsten A, Lindahl B, Wallentin L, Siegbahn A. Raised interleukin-10 is an indicator of poor outcome and enhanced systemic inflammation in patients with acute coronary syndrome. Heart. 2008;94:724-729.
52. Welsh P, Murray HM, Ford I, et al. Circulating interleukin-10 and risk of cardiovascular events: A prospective study in the elderly at risk. Arterioscler Thromb Vasc Biol. 2011;31:2338-2344.